Table 1 Patient characteristics.

Total no. of patients

26

11

37

Sex

0.48

   Male

15 (57.7)

3 (27.3)

18 (48.6)

   Female

11 (42.3)

8 (72.7)

19 (51.4)

Race

0.35

   White

15 (57.7)

10 (90.9)

25 (67.6)

   Hispanic

6 (23.0)

1 (9.1)

7 (18.9)

   African American

4 (15.4)

0 (0)

4 (10.8)

   Asian

1 (3.8)

0 (0)

1 (2.7)

Age in years at the time of treatment, mean ± SD (range)

42.3 ± 12.8 (14-72)

43.8 ± 6.4 (37-55)

42.7 ± 11.4 (14-72)

0.87

Tumor size in cm, median (range)

14.9 (6-23.3)

Disease site

   Lower extremity

23 (88.5)

   Neck

1 (3.8)

   Retroperitoneum

1 (3.8)

   Perineum

1 (3.8)

Number of disease sites

Single site (abdominal cavity, bone ^a , heart, mediastinum)

5 (45.5)

2 sites ^b

5 (45.5)

3 sites ^c

1 (9.1)

Tumor side

   Left

15 (57.7)

   Right

11 (42.3)

Hypercellular round cell tumor

1 (3.8)

1 (9.1)

2 (5.4)

0.82

Chemotherapy

   Median no. of chemotherapy cycles, median (range)

6 (4-6)

6 (5-8)

6 (4-8)

0.02

   Intensified doxorubicin dose (90 mg/m²)

8 (30.7)

3 (27.2)

11 (33.3)

1.00

Surgery (R0 intent)

26 (100)

   Free margins

21 (80.8)

   Positive margins (R1)

5 (19.2)

Radiotherapy

   Before surgery

21 (80.8)

   After surgery

5 (19.2)